The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.
Barbara L MeloskyParneet CheemaRosalyn A JuergensNatasha B LeighlGeoffrey LiuPaul Wheatley-PriceAdrian SacherStephanie SnowMing-Sound TsaoDeanna McLeodQuincy Siu-Chung ChuPublished in: Therapeutic advances in medical oncology (2021)
Adjuvant osimertinib used alone or following platinum-based chemotherapy is now recommended in patients with stage II-IIIA EGFR-mutated NSCLC.